BRIEF-Beigene Provides Update On The Ociperlimab (Bgb-A1217) Clinical Development Program

Reuters2025-04-03

April 3 (Reuters) - Beigene Ltd 688235.SS:

BEIGENE PROVIDES UPDATE ON THE OCIPERLIMAB (BGB-A1217) CLINICAL DEVELOPMENT PROGRAM
BEIGENE LTD - TO DISCONTINUE CLINICAL DEVELOPMENT OF OCIPERLIMAB FOR LUNG CANCER
BEIGENE LTD - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS TERMINATION OF PHASE 3 ADVANTIG-302 TRIAL
BEIGENE LTD - STUDY UNLIKELY TO MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL

Source text: ID:nBw2yCT0na

Further company coverage: 688235.SS

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2524237692?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-03 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524237692","market":"us","top_or_hot":-1,"title":"BRIEF-Beigene Provides Update On The Ociperlimab (Bgb-A1217) Clinical Development Program","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Beigene Provides Update On The Ociperlimab (Bgb-A1217) Clinical Development Program</title></head><body><p><span>April 3 (Reuters)</span><span> - </span>Beigene Ltd <span>688235.SS</span>:</p><ul><li><p>BEIGENE PROVIDES UPDATE ON THE OCIPERLIMAB (BGB-A1217) CLINICAL DEVELOPMENT PROGRAM</p></li><li><p>BEIGENE LTD - TO DISCONTINUE CLINICAL DEVELOPMENT OF OCIPERLIMAB FOR LUNG CANCER</p></li><li><p>BEIGENE LTD - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS TERMINATION OF PHASE 3 ADVANTIG-302 TRIAL</p></li><li><p>BEIGENE LTD - STUDY UNLIKELY TO MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL</p></li></ul><p>Source text: <span>ID:nBw2yCT0na</span></p><p>Further company coverage: <span>688235.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Beigene Provides Update On The Ociperlimab (Bgb-A1217) Clinical Development Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Beigene Provides Update On The Ociperlimab (Bgb-A1217) Clinical Development Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-03 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Beigene Provides Update On The Ociperlimab (Bgb-A1217) Clinical Development Program</title></head><body><p><span>April 3 (Reuters)</span><span> - </span>Beigene Ltd <span>688235.SS</span>:</p><ul><li><p>BEIGENE PROVIDES UPDATE ON THE OCIPERLIMAB (BGB-A1217) CLINICAL DEVELOPMENT PROGRAM</p></li><li><p>BEIGENE LTD - TO DISCONTINUE CLINICAL DEVELOPMENT OF OCIPERLIMAB FOR LUNG CANCER</p></li><li><p>BEIGENE LTD - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS TERMINATION OF PHASE 3 ADVANTIG-302 TRIAL</p></li><li><p>BEIGENE LTD - STUDY UNLIKELY TO MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL</p></li></ul><p>Source text: <span>ID:nBw2yCT0na</span></p><p>Further company coverage: <span>688235.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688235","symbol_name":"百济神州","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nTUAYY9YR:1","article_id":"2524237692","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524237692","pubTimestamp":1743677932,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Beigene Provides Update On The Ociperlimab (Bgb-A1217) Clinical Development ProgramApril 3 (Reuters) - Beigene Ltd 688235.SS:BEIGENE PROVIDES UPDATE ON THE OCIPERLIMAB (BGB-A1217) CLINICAL DEVEL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","BK0239":"医药制造"},"translate_title":"简介-百济神州提供Ociperlimab(Bgb-A1217)临床开发计划的最新信息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":0.9},"content_text":"BRIEF-Beigene Provides Update On The Ociperlimab (Bgb-A1217) Clinical Development ProgramApril 3 (Reuters) - Beigene Ltd 688235.SS:BEIGENE PROVIDES UPDATE ON THE OCIPERLIMAB (BGB-A1217) CLINICAL DEVELOPMENT PROGRAMBEIGENE LTD - TO DISCONTINUE CLINICAL DEVELOPMENT OF OCIPERLIMAB FOR LUNG CANCERBEIGENE LTD - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS TERMINATION OF PHASE 3 ADVANTIG-302 TRIALBEIGENE LTD - STUDY UNLIKELY TO MEET PRIMARY ENDPOINT OF OVERALL SURVIVALSource text: ID:nBw2yCT0naFurther company coverage: 688235.SS ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2524237692","isCrawlerRequest":true}